TET2 mutations are frequent in patients with AML, myelodysplastic syndromes (MDS) and chronic myelocytic leukaemia (CML), while TET1 and TET3 mutations are rare [42, 43]. This evidence concerns the gene TET2 and myelodysplastic syndrome.